Chondrosarcoma Treatment Market Size in the 7MM was ~USD 8.5 Million in 2023, is expected to grow by 2034, and estimates DelveInsight | Akorn, Inc., Epizyme, Inc., Mylan N.V., AbbVie Inc., Abbott, Baxter, Bayer AG, Agios, Inc., Novartis AG, Hoffmann-La Ro

DelveInsight's "Chondrosarcoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Chondrosarcoma, historical and forecasted epidemiology as well as the Chondrosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Discover Key Insights into the Chondrosarcoma Market with DelveInsight's In-Depth Report @ Chondrosarcoma Market Size- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chondrosarcoma Market Report
• Among the 7MM, the US accounted for the highest incident cases of chondrosarcoma in 2023.
• In 2023, the total Incident cases of Chondrosarcoma were approximately 1,300 cases in the US, which is expected to grow during the forecast period.
• Among EU4 and the UK, France accounted for the highest number of Chondrosarcoma Incident cases, while Spain accounted for the least Incident cases.
• Among the stage-specific incident cases of chondrosarcoma, localized cases contribute the most in Japan.
• As per analysis, Conventional chondrosarcomas represent ∼80% of all chondrosarcomas.
• According to DelveInsight, Chondrosarcoma market size is expected to grow at a decent CAGR by 2032.
• The leading Chondrosarcoma companies such as Akorn, Inc., Epizyme, Inc., Mylan N.V., AbbVie Inc., Abbott, Baxter, Bayer AG, Agios, Inc., Novartis AG, Hoffmann-La Roche Ltd., AEterna Zentaris Inc., Acorn Research Group, Agios Pharmaceuticals, Inc., Infinity Pharmaceuticals, and others.
• Promising Chondrosarcoma Therapies such as Pazopanib, INBRX-109, Trabectedin, AG-120, and others.

Stay ahead in the Chondrosarcoma Therapeutics Market with DelveInsight's Strategic Report @ Chondrosarcoma Market Outlook- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chondrosarcoma Epidemiology Segmentation in the 7MM
• Total Incident cases of Chondrosarcoma
• Primary Chondrosarcoma cases
• Grade-specific cases of Chondrosarcoma
• Mutation-specific cases of Chondrosarcoma
• Stage-specific cases of Chondrosarcoma

Download the report to understand which factors are driving Chondrosarcoma epidemiology trends @ Chondrosarcoma Prevalence- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Emerging Chondrosarcoma Drugs
• INBRX-109: Inhibrx
INBRX-109 is the most advanced therapeutic candidate of Inhibrx and is designed to target tumor-biased direct cell death induction by DR5 activation in numerous cancer types. DR5 is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). DR5 activation naturally eliminates damaged and/or neoplastic cells; normal cells are less sensitive to DR5-mediated cell death. INBRX-109 is a tetravalent DR5 agonistic antibody that can potentize DR5 through efficient receptor clustering, causing cell death. Currently, the drug is being evaluated in a potentially registration-enabling Phase II trial, and the company anticipates topline data readout from this pivotal trial by the second half of 2024, which will pave the path to approval in chondrosarcoma by 2025.

• TIBSOVO (ivosidenib): Servier
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor developed by Servier. A Phase III, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib is underway for participants aged 18 years and older with locally advanced or metastatic conventional chondrosarcoma harboring an IDH1 mutation, whether untreated or previously treated with one systemic treatment regimen. It is expected to be completed by 2031.

Chondrosarcoma Drugs Market Insights
Novel IDH inhibitors like AG-120 (ivosidenib) are showing potential in Phase III trials, particularly for patients with IDH1 mutations, with encouraging clinical activity observed. Additionally, targeting the Hedgehog pathway is being explored, although clinical trial results have been mixed. Inhibitors of the SRC pathway, such as dasatinib, demonstrate therapeutic benefits in preclinical studies, while inhibition of the PI3K-Akt-mTOR pathway shows promise in suppressing tumor progression. Histone deacetylase inhibitors and angiogenesis inhibitors also offer potential avenues for treatment, with ongoing research focusing on their efficacy in chondrosarcoma.

Get In-Depth Knowledge on Chondrosarcoma Market Trends and Forecasts with DelveInsight @ Chondrosarcoma Treatment Market- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chondrosarcoma Market Outlook
The current management of chondrosarcoma depends on the type, the grade, and the location of the tumor, while the best predictor of clinical behavior is the grading system from I to III. It is well-established that surgical treatment is the best and the only treatment for chondrosarcoma, as other treatments, such as radiotherapy and chemotherapy, are rendered unresponsive and refractory. Curettage, radical resection, and amputation are the primary surgical treatment options, while these procedures often require considerable judgment and are based on factors such as the size and site of the lesion and its degree of malignancy.

Scope of the Chondrosarcoma Market Report
• Coverage- 7MM
• Chondrosarcoma Companies- Akorn, Inc., Epizyme, Inc., Mylan N.V., AbbVie Inc., Abbott, Baxter, Bayer AG, Agios, Inc., Novartis AG, Hoffmann-La Roche Ltd., AEterna Zentaris Inc., Acorn Research Group, Agios Pharmaceuticals, Inc., Infinity Pharmaceuticals, and others.
• Chondrosarcoma Therapies- Pazopanib, INBRX-109, Trabectedin, AG-120, and others.
• Chondrosarcoma Market Access & Reimbursements, Unmet Needs and Perspectives
• Chondrosarcoma SWOT Analysis and KOL Views

Unlock Strategic Insights with DelveInsight's Comprehensive Chondrosarcoma Market Report @ Chondrosarcoma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Executive Summary
3. Chondrosarcoma Competitive Intelligence Analysis
4. Chondrosarcoma Market Overview at a Glance
5. Chondrosarcoma Disease Background and Overview
6. Chondrosarcoma Patient Journey
7. Chondrosarcoma Epidemiology and Patient Population
8. Chondrosarcoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Chondrosarcoma Unmet Needs
10. Key Endpoints of Chondrosarcoma Treatment
11. Chondrosarcoma Marketed Products
12. Chondrosarcoma Emerging Therapies
13. Chondrosarcoma Seven Major Market Analysis
14. Attribute Analysis
15. Chondrosarcoma Market Outlook (7 major markets)
16. Chondrosarcoma Access and Reimbursement Overview
17. KOL Views on the Chondrosarcoma Market
18. Chondrosarcoma Market Drivers
19. Chondrosarcoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Learn more about the emerging Chondrosarcoma therapies & key companies @ Chondrosarcoma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/chondrosarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of the Top Selling Market Research Reports in 2025
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
vulvar cancer market- https://www.delveinsight.com/report-store/vulvar-cancer-pipeline-insight
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
sepsis market- https://www.delveinsight.com/report-store/sepsis-market-insight
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
cart pipeline- https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape
dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
total knee arthroplasty market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.